Trodusquemine (MSI-1436) Restores Metabolic Flexibility and Mitochondrial Dynamics in Insulin-Resistant Equine Hepatic Progenitor Cells (HPCs)
Authors: B. Qasem, A. Dąbrowska, J. Króliczewski, Jacek Łyczko, Krzysztof Marycz
Journal: Cells
Summary
# Editorial Summary Equine metabolic syndrome represents a persistent challenge in veterinary practice, with insulin dysregulation and hepatic dysfunction at its core. Researchers investigated whether trodusquemine (MSI-1436), a protein tyrosine phosphatase inhibitor, could reverse metabolic dysfunction in equine hepatic progenitor cells exposed to lipotoxic stress (palmitate). In cultured cells, MSI-1436 restored glucose uptake, enhanced cell survival under lipotoxic conditions, and triggered beneficial changes in mitochondrial structure and quantity through upregulation of key regulatory proteins (SIRT1, PINK1, MFN1, and MFN2). These findings suggest that pharmacological modulation of hepatic cell metabolism via PTP1B inhibition may offer a novel therapeutic avenue for managing EMS and metabolic dysfunction in affected horses, though further investigation in vivo would be needed to establish clinical efficacy and dosing protocols. For practitioners managing insulin-dysregulated horses, this work highlights the hepatic mitochondrial dysfunction underlying metabolic disease and points towards potential future treatments beyond current dietary and management-based interventions.
Read the full abstract on PubMed
Practical Takeaways
- •PTP1B inhibitors like MSI-1436 show promise as a potential therapeutic avenue for managing equine metabolic syndrome at the molecular level, though clinical translation remains years away
- •This research identifies mitochondrial dysfunction as a key mechanism in EMS-related insulin resistance, which may inform future nutritional and management strategies targeting metabolic health
- •Current findings are limited to cell culture models; clinical efficacy and safety in live horses has not been established
Key Findings
- •Trodusquemine (MSI-1436) promoted cell cycle entry and protected equine hepatic progenitor cells from palmitate-induced apoptosis
- •MSI-1436 increased glucose uptake by upregulating SIRT1 expression, suggesting improved insulin sensitivity
- •MSI-1436 enhanced mitochondrial dynamics and biogenesis by increasing expression of PINK1, MFN1, and MFN2
- •Treatment restored metabolic flexibility in lipotoxic hepatic progenitor cells through mitochondrial reorganization